CT-2103
Term · Oncology and biomedicine · MLC-T-ONC-002163
A form of the anticancer drug paclitaxel combined with a protein called poliglumex that may have fewer side effects and work better than paclitaxel. It is being studied in the treatment of breast cancer, ovarian cancer, lung cancer, and other types of cancer. It belongs to the family of drugs called mitotic inhibitors. Also called paclitaxel poliglumex, paclitaxel polyglutamate, and Xyotax.
| Identifier | MLC-T-ONC-002163 |
|---|---|
| Field | Oncology and biomedicine |
| Expansions | paclitaxel poliglumex; paclitaxel polyglutamate; Xyotax |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-002163",
"term": "CT-2103",
"field": "Oncology and biomedicine",
"definition": "A form of the anticancer drug paclitaxel combined with a protein called poliglumex that may have fewer side effects and work better than paclitaxel. It is being studied in the treatment of breast cancer, ovarian cancer, lung cancer, and other types of cancer. It belongs to the family of drugs called mitotic inhibitors. Also called paclitaxel poliglumex, paclitaxel polyglutamate, and Xyotax.",
"expansions": [
"paclitaxel poliglumex",
"paclitaxel polyglutamate",
"Xyotax"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/ct-2103/"
}
Record 5,477 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.